---
title: "Retatrutide FAQ: Trials, Doses & Weight Loss Numbers | BodyHackGuide"
url: https://www.bodyhackguide.co/guides/retatrutide-faq
description: "Straight answers on retatrutide: phase 3 TRIUMPH trials, weight loss by dose, side effects, dosing and when it might be approved. All figures from the trials."
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

FAQ · Research guide

# Retatrutide FAQ

Common questions on the trials, the doses and the weight loss numbers.

Every figure here comes straight from the published phase 2 and phase 3 (TRIUMPH) trials, the same numbers as the Retatrutide Phase 3 Research Guide (https://www.bodyhackguide.co/guides/retatrutide-phase-3-card).

01 / QUESTION

## What is retatrutide?

Retatrutide is a once-weekly injectable research compound from Eli Lilly that acts on three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere yet and is still investigational.

02 / QUESTION

## How much weight did people lose in the phase 3 trials?

At 80 weeks in TRIUMPH-1 (obesity, no diabetes): 19.0% at 4 mg, 25.9% at 9 mg, 28.3% at 12 mg. In TRIUMPH-2 (obesity + type 2 diabetes): 12.7% at 4 mg, 19.1% at 9 mg, 20.8% at 12 mg. Placebo lost 4.0%.

In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight.

03 / QUESTION

## What are the TRIUMPH trials?

TRIUMPH is the phase 3 program. TRIUMPH-1 put 2,339 people with obesity but no diabetes on 80 weeks and the 12 mg group lost 28.3%. TRIUMPH-2 put 1,152 people with obesity and type 2 diabetes on 80 weeks and 12 mg lost 20.8%. TRIUMPH-3 covered 1,949 people with severe obesity plus heart disease (22.6% at 12 mg over 80 weeks), and TRIUMPH-4 covered 445 people with obesity and knee osteoarthritis (28.7% at 12 mg over 68 weeks).

04 / QUESTION

## What did the earlier phase 2 trial show?

338 people over 48 weeks. The 12 mg group lost 24.2% of body weight, already ahead of what TRIUMPH-1 later confirmed at week 48 (24.2%).

05 / QUESTION

## How fast does the weight come off?

On 12 mg: 17.5% at week 24, 24.2% at week 48, 28.3% at week 80. Weeks 24 and 48 are from the phase 2 trial, week 80 from TRIUMPH-1. The curve was still dropping at week 48 with no plateau; judge it at months, not weeks, because the first 16 weeks are mostly titration.

06 / QUESTION

## How is retatrutide dosed in the trials?

In the phase 3 TRIUMPH trials, every retatrutide arm started at 2 mg once weekly and stepped up every four weeks until it reached its target dose, on this schedule: 2 mg in weeks 1-4, 4 mg in weeks 5-8, 6 mg in weeks 9-12, 9 mg in weeks 13-16 and, for the 12 mg arm, 12 mg from week 17. The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) used escalation steps different from those of the phase 3 TRIUMPH trials: its 12 mg arm stepped through 2, 4 and 8 mg before reaching 12 mg.

2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there is no 2 mg result.

07 / QUESTION

## What are the most common side effects?

GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases, which is why the four-week holds exist.

11-18% quit the 12 mg dose over side effects (11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4; placebo was 4-5%). Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo.

08 / QUESTION

## What is dysesthesia?

An altered skin sensation unique to this drug class. At 12 mg it affected 7-21% of participants: 7.3% in TRIUMPH-2 and 20.9% in TRIUMPH-4.

09 / QUESTION

## Does retatrutide raise heart rate?

Phase 2 recorded a peak resting heart rate rise of +6.7 beats per minute at 12 mg, highest around week 24 and easing after. Approved drugs in the same class carry label warnings for pancreatitis, gallbladder disease and thyroid C-cell tumors (seen in rodents).

10 / QUESTION

## Is retatrutide approved?

No. It is not approved in any country as of now. The realistic timeline: Lilly files the BLA with the FDA in Q1 2027, standard review adds 10-12 months, making late 2027 the earliest realistic approval.

11 / QUESTION

## How do the retatrutide trial dose steps translate into reconstitution arithmetic?

In a laboratory, 10 mg of peptide dissolved in 1 mL of bacteriostatic water gives a 10 mg per mL solution, and on a U-100 syringe, 10 units (0.1 mL) of that solution contain 1 mg of peptide, so the 2, 4, 6 and 9 mg steps of the phase 3 TRIUMPH dose schedule for retatrutide correspond to 20, 40, 60 and 90 units. At 10 mg per mL, the 12 mg step of the TRIUMPH schedule for retatrutide corresponds to 120 units (1.2 mL), which is more than a 1 mL U-100 syringe holds and more than a vial of 10 mg in 1 mL contains; at 15 mg per mL (30 mg of peptide in 2 mL), 12 mg corresponds to 80 units. BodyHackGuide's reconstitution calculator takes a vial size, a water volume and an amount and returns the mg per mL concentration and the number of syringe units that contain that amount. Converting the TRIUMPH dose steps for retatrutide into syringe units is research arithmetic for laboratory use, not a dosing instruction.

12 / QUESTION

## What did the retatrutide trials measure?

The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) and the phase 3 TRIUMPH trials measured body weight, waist circumference, heart rate, A1C, fasting glucose and lipids, each at baseline and at scheduled visits.

MORE

## Keep reading

- Retatrutide Phase 3 Research Guide
  The TRIUMPH-1 and TRIUMPH-2 results on one page: titration, results by dose, reconstitution math.
  https://www.bodyhackguide.co/guides/retatrutide-phase-3-card
- Retatrutide price comparison
  Current listings, price per mg and vendor trust scores for retatrutide.
  https://www.bodyhackguide.co/compound/retatrutide

For research and educational purposes only. Retatrutide is investigational and not approved for human use in any jurisdiction. Not medical advice.

BodyHackGuide (https://www.bodyhackguide.co/)

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved.

- Terms: https://www.bodyhackguide.co/terms
- Privacy: https://www.bodyhackguide.co/privacy

## Structured data

```json
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "url": "https://www.bodyhackguide.co/guides/retatrutide-faq",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is retatrutide?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Retatrutide is a once-weekly injectable research compound from Eli Lilly that acts on three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere yet and is still investigational."
      }
    },
    {
      "@type": "Question",
      "name": "How much weight did people lose in the phase 3 trials?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "At 80 weeks in TRIUMPH-1 (obesity, no diabetes): 19.0% at 4 mg, 25.9% at 9 mg, 28.3% at 12 mg. In TRIUMPH-2 (obesity + type 2 diabetes): 12.7% at 4 mg, 19.1% at 9 mg, 20.8% at 12 mg. Placebo lost 4.0%. In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight."
      }
    },
    {
      "@type": "Question",
      "name": "What are the TRIUMPH trials?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "TRIUMPH is the phase 3 program. TRIUMPH-1 put 2,339 people with obesity but no diabetes on 80 weeks and the 12 mg group lost 28.3%. TRIUMPH-2 put 1,152 people with obesity and type 2 diabetes on 80 weeks and 12 mg lost 20.8%. TRIUMPH-3 covered 1,949 people with severe obesity plus heart disease (22.6% at 12 mg over 80 weeks), and TRIUMPH-4 covered 445 people with obesity and knee osteoarthritis (28.7% at 12 mg over 68 weeks)."
      }
    },
    {
      "@type": "Question",
      "name": "What did the earlier phase 2 trial show?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "338 people over 48 weeks. The 12 mg group lost 24.2% of body weight, already ahead of what TRIUMPH-1 later confirmed at week 48 (24.2%)."
      }
    },
    {
      "@type": "Question",
      "name": "How fast does the weight come off?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "On 12 mg: 17.5% at week 24, 24.2% at week 48, 28.3% at week 80. Weeks 24 and 48 are from the phase 2 trial, week 80 from TRIUMPH-1. The curve was still dropping at week 48 with no plateau; judge it at months, not weeks, because the first 16 weeks are mostly titration."
      }
    },
    {
      "@type": "Question",
      "name": "How is retatrutide dosed in the trials?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "In the phase 3 TRIUMPH trials, every retatrutide arm started at 2 mg once weekly and stepped up every four weeks until it reached its target dose, on this schedule: 2 mg in weeks 1-4, 4 mg in weeks 5-8, 6 mg in weeks 9-12, 9 mg in weeks 13-16 and, for the 12 mg arm, 12 mg from week 17. The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) used escalation steps different from those of the phase 3 TRIUMPH trials: its 12 mg arm stepped through 2, 4 and 8 mg before reaching 12 mg. 2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there is no 2 mg result."
      }
    },
    {
      "@type": "Question",
      "name": "What are the most common side effects?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases, which is why the four-week holds exist. 11-18% quit the 12 mg dose over side effects (11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4; placebo was 4-5%). Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo."
      }
    },
    {
      "@type": "Question",
      "name": "What is dysesthesia?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "An altered skin sensation unique to this drug class. At 12 mg it affected 7-21% of participants: 7.3% in TRIUMPH-2 and 20.9% in TRIUMPH-4."
      }
    },
    {
      "@type": "Question",
      "name": "Does retatrutide raise heart rate?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Phase 2 recorded a peak resting heart rate rise of +6.7 beats per minute at 12 mg, highest around week 24 and easing after. Approved drugs in the same class carry label warnings for pancreatitis, gallbladder disease and thyroid C-cell tumors (seen in rodents)."
      }
    },
    {
      "@type": "Question",
      "name": "Is retatrutide approved?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No. It is not approved in any country as of now. The realistic timeline: Lilly files the BLA with the FDA in Q1 2027, standard review adds 10-12 months, making late 2027 the earliest realistic approval."
      }
    },
    {
      "@type": "Question",
      "name": "How do the retatrutide trial dose steps translate into reconstitution arithmetic?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "In a laboratory, 10 mg of peptide dissolved in 1 mL of bacteriostatic water gives a 10 mg per mL solution, and on a U-100 syringe, 10 units (0.1 mL) of that solution contain 1 mg of peptide, so the 2, 4, 6 and 9 mg steps of the phase 3 TRIUMPH dose schedule for retatrutide correspond to 20, 40, 60 and 90 units. At 10 mg per mL, the 12 mg step of the TRIUMPH schedule for retatrutide corresponds to 120 units (1.2 mL), which is more than a 1 mL U-100 syringe holds and more than a vial of 10 mg in 1 mL contains; at 15 mg per mL (30 mg of peptide in 2 mL), 12 mg corresponds to 80 units. BodyHackGuide's reconstitution calculator takes a vial size, a water volume and an amount and returns the mg per mL concentration and the number of syringe units that contain that amount. Converting the TRIUMPH dose steps for retatrutide into syringe units is research arithmetic for laboratory use, not a dosing instruction."
      }
    },
    {
      "@type": "Question",
      "name": "What did the retatrutide trials measure?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) and the phase 3 TRIUMPH trials measured body weight, waist circumference, heart rate, A1C, fasting glucose and lipids, each at baseline and at scheduled visits."
      }
    }
  ]
}
```